Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

Study Overview
=================
Brief Summary
-----------------
To observe the effectiveness and safety of different therapies-non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) or antiplatelet agents and non-antithrombotic therapy - for the treatment of VT.

Official Title
-----------------
Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

Conditions
-----------------
Ventricular Thrombus

Intervention / Treatment
-----------------
* Drug: non-vitamin K antagonist oral anticoagulants (NOACs)
* Drug: vitamin K antagonists (VKAs)
* Drug: antiplatelet agents
* Other: non-antithrombotic therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with ventricular thrombus(VT), regardless of sex, basic diseases, occupation or education; The VT should be found newly within 3 months; The observational phase should last until the time that patients who had achieved thrombus resolution. The following up period after the phase ended should continue for at least 3 months. Exclusion Criteria: Individuals received standard antithrombotic therapy within 4 weeks; Individuals received the thrombectomy therapy, ventricular aneurysm resection or heart transplantation within 6 weeks since the VT was found in the first time; Had a long history of VT more than three months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non-vitamin K antagonist oral anticoagulants (NOACs)<br> | Drug: non-vitamin K antagonist oral anticoagulants (NOACs)<br>* Collecting information of patients with VT who received NOACs<br>|
| vitamin K antagonists (VKAs)<br> | Drug: vitamin K antagonists (VKAs)<br>* Collecting information of patients with VT who received VKAs<br>|
| antiplatelet agents<br> | Drug: antiplatelet agents<br>* Collecting information of patients with VT who received antiplatelet agents<br>|
| non-antithrombotic therapy<br> | Other: non-antithrombotic therapy<br>* Collecting information of patients with VT without any antithrombotic therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thrombus resolution in 12 weeks follow-up | Thrombus resolution in 12 weeks follow-up | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thrombus resolution in 6 weeks follow-up | Thrombus resolution in 6 weeks follow-up | 6 weeks | 
| Thrombus resolution in 6 months follow-up | Thrombus resolution in 6 months follow-up | 6 months | 
| Thrombus resolution in 12 months follow-up | Thrombus resolution in 12 months follow-up | 12 months | 
| Thromboembolism events | Thromboembolism events | 12 months | 
| Bleeding | Bleeding | 12 months | 
| All-cause death | All-cause death | 12 months |